Post-Market Surveillance Plan is a manufacturer-authored document that defines how real-world safety and performance data will be collected, analyzed, and acted upon after a medical device enters the market. It specifies data sources, collection intervals, evaluation criteria, and the threshold conditions that trigger a corrective or safety response.
What is a Post-Market Surveillance Plan?
A Post-Market Surveillance Plan (PMS Plan) is the documented framework governing ongoing monitoring of a device’s real-world performance. It is the front-end component of a manufacturer’s Post-Market Surveillance (PMS) system, specifying what will be monitored and how, before the device ships. The plan governs two required output documents: the Post-Market Surveillance Report (PMSR) for Class I devices and the Periodic Safety Update Report (PSUR) for Class IIa, IIb, and III devices, both under EU MDR 2017/745.
The plan is not a record of what has happened. It is a forward-looking specification that answers: what data will be collected, how, and what the manufacturer will do when findings cross a defined threshold.
Why does the Post-Market Surveillance Plan matter in medical device development
EU MDR 2017/745 Article 83 requires every manufacturer to operate a PMS system regardless of device class. The PMS Plan is the written proof that the system is real and governed. A missing or inadequate plan is a Notified Body audit finding that can block Technical Documentation approval or halt a Certificate renewal.
Beyond compliance, the plan is an early-warning mechanism. Without defined data sources and evaluation intervals, safety signals accumulate silently in complaint logs until an incident demands a Field Safety Corrective Action (FSCA). FSCAs trigger regulatory visibility across markets and carry remediation costs that a well-designed PMS system is built to prevent.
For Class IIb and Class III devices, the plan must also define the Post-Market Clinical Follow-Up (PMCF) scope: the structured clinical data program that sustains conformity under EU MDR beyond initial approval.
Key components of a Post-Market Surveillance Plan
A compliant PMS Plan aligns with EU MDR Annex III, ISO 13485 Section 8.2, and, for U.S.-market devices, FDA requirements under 21 CFR Parts 803 and 820. The plan must cover:
Scope
The specific device model, configuration, and intended use the plan applies to.
Data sources
Complaint records, adverse event reports, EUDAMED vigilance data, published clinical literature, post-market registries, equivalent-device data, and customer service records.
Collection methods and frequency
How each source will be accessed, who owns the retrieval process, and how often data will be evaluated.
Evaluation criteria
Thresholds and statistical methods for determining whether a data pattern constitutes a signal. These must trace to the benefit-risk assessment in the ISO 14971 risk management file.
PMCF scope
For devices relying on clinical evidence for conformity, the plan must describe PMCF activities, methodology, acceptance criteria, and timelines.
Output documents
The PMSR or PSUR, PMCF Evaluation Report, updates to the risk management file, and any labeling or IFU changes the evaluation requires.
The plan is a living document. It must be revised when the risk file changes, a safety signal appears, or the device’s configuration or intended use is modified.
Common challenges and best practices
Starting too late
PMS planning should begin during design development, well before CE marking. Baseline performance criteria are far easier to define before market entry than after the first complaints arrive.
Plans that list without specifying
Enumerating data sources without defining retrieval methods, ownership, or evaluation frequency does not satisfy a Notified Body. Each source needs an owner, a process, and a schedule.
Disconnection from the risk file
The PMS Plan’s evaluation criteria must trace to the ISO 14971 benefit-risk assessment. If they operate independently, there is no documented pathway for post-market data to update risk controls, and Notified Bodies check this linkage directly.
Treating PMCF as optional
EU MDR’s default is that PMCF will be conducted. A manufacturer wishing to omit it must produce a specific, justified rationale in writing. Silence is not a valid position.
Cross-functional review before launch, with input from clinical, regulatory, and engineering, produces plans that hold up to external scrutiny better than documents assembled by RA in isolation.
How SJML helps with Post-Market Surveillance Plans
SJML’s QARA team develops and maintains PMS Plans for manufacturers across Class I, II, and III devices. Services include plan authoring, PMSR and PSUR drafting, PMCF plan design, adverse event monitoring, EUDAMED submissions, and vigilance management, including FSCA coordination. Plans are structured to satisfy EU MDR, FDA, and country-specific regulatory requirements. For clients needing end-to-end managed compliance, SJML integrates complaint handling and CAPA linkage into the full PMS cycle.
Frequently asked questions
A Post-Market Surveillance Plan is the document that defines what data will be collected, how, and when. A Periodic Safety Update Report (PSUR) is the output produced after the data has been analyzed. The plan governs the cycle; the PSUR captures the findings. Under EU MDR, PSURs are required for Class IIa, IIb, and III devices.
Before the device reaches the market. EU MDR 2017/745 Article 83 treats the PMS system and its governing plan as a pre-market conformity requirement, not a post-sale obligation. Notified Bodies expect a completed, device-specific PMS Plan during Technical Documentation review, not a generic placeholder.
Yes. EU MDR requires manufacturers of all device classes to maintain a PMS system. Class I devices produce a Post-Market Surveillance Report (PMSR) rather than a PSUR, but the underlying PMS Plan is mandatory across all device classes without exception.
The plan must be reviewed when the risk file changes, when a safety signal is identified, or when the device’s configuration or intended use is modified. Annual review covers most routine update triggers and is standard practice for regulated device programs under ISO 13485.
For devices where clinical evidence is required for conformity, yes. EU MDR Annex XIV Part B requires the PMS Plan to include or reference a PMCF plan, specifying activities, methodology, and rationale. If PMCF is not applicable, that determination must be justified and documented in writing.
Related terms
- Post-Market Clinical Follow-Up (PMCF)
- Periodic Safety Update Report (PSUR)
- Post-Market Surveillance Report (PMSR)
- Field Safety Corrective Action (FSCA)
- Risk Management File
